SCM
HRMY icon

Suvretta Capital Management’s Harmony Biosciences HRMY Stock Holding History

Suvretta Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-58,734
Closed -$2.86M – 79
2022
Q2 		$2.86M Buy
+58,734
New +$2.64M 0.11% 74
2020
Q4 		– Sell
-12,500
Closed -$424K – 114
2020
Q3 		$424K Buy
+12,500
New +$456K 0.01% 93

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Suvretta Capital Management's HRMY Position: Q3 2022 in Review

Suvretta Capital Management sold out of Harmony Biosciences (HRMY) in Q3 2022, closing a stake of 58,734 shares — an estimated $2.86M sold.

Suvretta Capital Management first reported a position in HRMY in Q3 2020 and held it in 2 quarters. The position peaked at $2.86M in Q2 2022. 203 funds tracked by Wall St. Rank hold HRMY as of Q3 2022.

  • Suvretta Capital Management reported no remaining Harmony Biosciences position as of Q3 2022 after selling out during the quarter.
  • Suvretta Capital Management sold 58,734 Harmony Biosciences shares in Q3 2022, an estimated $2.86M.
  • Suvretta Capital Management first reported a position in Harmony Biosciences in Q3 2020 and held it in 2 quarters.
  • Suvretta Capital Management's Harmony Biosciences position peaked at $2.86M in Q2 2022.
  • 203 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2022.

Based on Suvretta Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.